Informa Life Sciences is organizing the 16th annual Immunogenicity & PK/PD Biomarkers Conference in Berlin, Germany on 26-27 September 2012.
With the increasing number of next-generation products, including biosimilars, different immunogenicity strategies need to be put in place in order to carefully evaluate immunogenicity. In addition, there is an industry movement from traditional immunogenicity testing to more clinical drug evaluation and risk assessment which is being applied by more and more big pharma. Understanding their strategies and how these approaches can improve immunogenicity prediction is essential to ensure product safety and approval.
Informa announce the new focus on PK/PD analysis, which is becoming an increasingly integrated approach in immunogenicity assessment. 2012 Immunogenicity event provides the latest strategies being applied by leading biopharm companies and demonstrating new data.
For more information, the website of the conference is: http://www.informa-ls.com/event/immunogenicity12